Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus INDICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus INDICLOR.
DUEXIS vs INDICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
INDICLOR is not a recognized drug; no standard dosing available.
None Documented
None Documented
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Category C
Category C
NSAID/H2 Antagonist Combination
NSAID